z-logo
open-access-imgOpen Access
Diabetic retinopathy – An update
Author(s) -
Abdulrahman A. Alghadyan
Publication year - 2011
Publication title -
saudi journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.359
H-Index - 25
eISSN - 2542-6680
pISSN - 1319-4534
DOI - 10.1016/j.sjopt.2011.01.009
Subject(s) - medicine , diabetic retinopathy , ophthalmology , macular edema , vitrectomy , ranibizumab , vitreous hemorrhage , panretinal photocoagulation , diabetes mellitus , dyslipidemia , neovascularization , laser coagulation , surgery , bevacizumab , retinal , visual acuity , angiogenesis , chemotherapy , endocrinology
Management of diabetes should involve both systemic and ocular aspects. Control of hyperglycemia, hypertension and dyslipidemia are of major role in the management of diabetic retinopathy. In the ocular part; laser treatment remains the cornerstone of treatment of diabetic macular edema (focal/grid), severe non-proliferative and proliferative diabetic retinopathy (panretinal photocoagulation). There is a strong support to combination therapy. Using one or two intravitreal injections such as anti-VEGF and or steroid to reduce central macular thickness followed by focal or grid laser to give a sustained response may offer an alternative to treatment in diabetic macular edema. Anti-VEGF were found to be effective as an adjunct therapy in proliferative diabetic retinopathy patient who is going to have vitrectomy for vitreous hemorrhage with neovascularization, panretinal photocoagulation, and other ocular surgery such as cases with neovascular glaucoma and cataract with refractory macular edema.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom